EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines

Spencer C Wei iD, Aaron J Cantor iD, Jack Walleshauser, Rina Mepani, Kory Melton, Ashil Bans, Prachi Khekare, Suhani Gupta, Jonathan Wang, Craig Soares iD, Radwan Kiwan, Jieun Lee und 14 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0317387 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Spencer C Wei und 25 weiteren Autor:innen. Beteiligte Einrichtung: Spotlight Therapeutics, Hayward, CA, USA. Hauptthemen laut MEDLINE: Gene Editing, Ribonucleoproteins, CRISPR-Cas Systems, CRISPR-Associated Protein 9. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Office of Extramural Research, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic medicines, including CRISPR/Cas technologies, extend tremendous promise for addressing unmet medical need in inherited retinal disorders and other indications; however, there remain challenges for the development of therapeutics. Herein, we evaluate genome editing by engineered Cas9 ribonucleoproteins (eRNP) in vivo via subretinal administration using mouse and pig animal models. Subretinal administration of adenine base editor and double strand break-inducing Cas9 nuclease eRNPs mediate genome editing in both species. Editing occurs in retinal pigmented epithelium (RPE) and photoreceptor cells, with favorable tolerability in both species. Using transgenic reporter strains, we determine that editing primarily occurs close to the site of administration, within the bleb region associated with subretinal injection. Our results show that subretinal administration of BE-eRNPs in mice mediates base editing of up to 12% of the total neural retina, with an average rate of 7% observed at the highest dose tested. In contrast, a substantially lower editing efficiency was observed in minipigs; even with direct quantification of only the treated region, a maximum base editing rate of 1.5%, with an average rate of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingRibonucleoproteinsCRISPR-Cas SystemsCRISPR-Associated Protein 9Genetic TherapyAnimalsMiceSwineRetinaRetinal Pigment EpitheliumDisease Models, Animal

Substanzen

RibonucleoproteinsCRISPR-Associated Protein 9

Autor:innen und Institutionen

  • Spotlight Therapeutics, Hayward, CA, USA.
  • McPherson Eye Research Institute, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Department of Pediatrics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Waisman Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.
  • Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.

ORCID-Profile: Spencer C Wei, Aaron J Cantor, Craig Soares, Krishanu Saha

Förderung

  • NINDS NIH HHS
  • Office of Extramural Research, National Institutes of Health

Zitieren

APA

Wei, S. C., Cantor, A. J., Walleshauser, J., Mepani, R., Melton, K., Bans, A., Khekare, P., Gupta, S., Wang, J., Soares, C., Kiwan, R., Lee, J., McCawley, S., Jani, V., Leong, W. I., Shahi, P. K., Chan, J., Boivin, P., Otoupal, P., …, & Silverman, A. P. (2025). Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines. PLOS One. https://doi.org/10.1371/journal.pone.0317387

Vancouver

Wei SC, Cantor AJ, Walleshauser J, Mepani R, Melton K, Bans A, et al. Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines. PLOS One. 2025. doi:10.1371/journal.pone.0317387

BibTeX
@article{Wei2025,
  author = {Wei, Spencer C and Cantor, Aaron J and Walleshauser, Jack and Mepani, Rina and Melton, Kory and Bans, Ashil and Khekare, Prachi and Gupta, Suhani and Wang, Jonathan and Soares, Craig and Kiwan, Radwan and Lee, Jieun and McCawley, Shannon and Jani, Vihasi and Leong, Weng In and Shahi, Pawan K and Chan, Jean and Boivin, Pierre and Otoupal, Peter and Pattnaik, Bikash R and Gamm, David M and Saha, Krishanu and Gowen, Benjamin G and Haak-Frendscho, Mary and Janatpour, Mary J and Silverman, Adam P},
  title = {Evaluation of subretinally delivered Cas9 ribonucleoproteins in murine and porcine animal models highlights key considerations for therapeutic translation of genetic medicines},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0317387}
}
Kostenlos starten →